CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading

EVP Joseph W LaPlume bought 25 CRL shares at $174.54; stock now $179.58, down 20.8% from 52-week high.

LaPlume purchased 25 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. at $174.54, a modest transaction representing a 0.1% increase in his 27.4K share position. The stock has risen $5.04 since the transaction date but remains -20.8% from its 52-week high of $226.77 and has declined -15.8% over the past 30 days. Notably, the company reported a negative full-year net income despite generating $1.0B in quarterly revenue with -0.8% annual growth, indicating underlying business headwinds. His prior trades at CRL (two sells in November 2023) occurred ahead of subsequent stock gains, timing those sales poorly; this small buy purchase follows a different pattern but its minuscule size (0.1% of holdings) limits its interpretive weight.

CRL COO Girshick Birgit buys 1,514 shares at $164.63; stock down 33.5% from 52-week high and -3.1% in 30 days.

Girshick Birgit, Corporate Executive VP & COO, purchased 1,514 shares of Charles River Laboratories at $164.63 on 2025-02-20, increasing her holdings by 2.8% to 55,058 shares. The purchase occurs as the stock has declined 33.5% from its 52-week high of $245.29 and fallen 3.1% over the past 30 days, trading at $163.02 currently. Her cross-ticker track record shows 1 prior buy with a 90-day return of +30.4%, and her single prior buy at CRL on 2023-11-20 also generated a +30.4% 90-day return. The company's fundamentals show declining annual revenue growth at -1.9%, a steeply elevated P/E of 815.10, and a market cap of $8.3B against quarterly revenue of $1.0B, suggesting a disconnect between current valuation and near-term earnings power.

CRL CEO Foster buys 6,075 shares at $165.01; stock down 33.5% from 52-week high, now $163.02

FOSTER JAMES C, the Chairman, President and CEO, purchased 6,075 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. at $165.01 on 2025-02-20, increasing his holdings from 177,564 to 183,639 shares. The purchase occurs as the stock trades at $163.02, down 33.5% from its 52-week high of $245.29 and down 16.7% over the past 90 days. Across his open-market trade history, Foster's prior sell at this ticker (2024-08-01) exhibited a 90-day return of -27.4%, which was well-timed, though his lone measurable buy outcome at CRL is not yet available. The company's fundamentals show annual revenue growth of -1.9%, with a notably elevated P/E of 815.10 relative to net income of $69,657,000.00, warranting scrutiny of earnings quality and sustainability.

Director Richard F Wallman sells complete stake: 7,621 shares for $1.6M at $216.17 average

Richard F Wallman, a Director, executed 3 separate sales totaling 7,621 shares for $1,647,418.25 on 2024-11-07, disposing of his entire CRL position. The blended average sale price of $216.17 sits near the current market price of $215.94, with the stock up 11.9% over the prior 30 days and 8.8% over 90 days. Wallman's cross-ticker track record shows 3 prior sells with a documented timing performance; however, his single prior CRL trade (a buy on 2023-08-24) was not well-timed at the 90-day mark, returning -1.9%. The complete liquidation of a director-held position warrants investor attention as a data point, though the absence of a scheduled trading plan designation leaves the transaction's timing context unclear.

CEO James Foster sold 25,000 CRL shares at $250.00 for $6.2M on 2024-08-01, reducing stake to 188.3K shares (-11.7%).

James C. Foster, Chairman, President and CEO of Charles River Laboratories, sold 25,000 shares at $250.00 on 2024-08-01, raising $6,250,000.00, which represents an 11.7% reduction in his post-transaction holdings to 188,251 shares. The sale occurred at a price point that was $23.60 above the current market price of $226.40, and the stock has since declined 4.2% over the 90-day period following the transaction, suggesting the sale preceded a broader pullback from the transaction price. While Foster's cross-ticker track record shows strong timing (100% win rate with +26.8% average 90-day returns on prior buys), his one prior buy at CRL on 2023-11-14 returned +26.8% over 90 days; this current sell-side transaction and the subsequent stock performance offer a contrasting data point for same-ticker assessment. The company's fundamentals remain solid with $1,011,560,000.00 in latest-quarter revenue and $72,960,000.00 in net income, with a P/E of 26.23, though the stock is currently -17.2% from its 52-week high of $273.43.